In addition, Takeuchi et al. found an increase in a subset of central memory CD4+ T cells, defined by the phenotype CD27+Fas-CD45RA-CCR7+, in blood of melanoma patients after anti-PD-1 treatment, which is associated with clinical responses [87]. This evidence concerns the gene FAS and melanoma.